British Virgin Islands vs Grenada: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
British Virgin Islands
0.2%
in 2024
Grenada
0.2%
in 2024
British Virgin Islands rank
78th
Grenada rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- British Virgin Islands
- Grenada
How they compare
British Virgin Islands currently reports 0.2% against 0.2% in Grenada, a difference of 0.0%.
Across all 10 years both countries report, Grenada has been ahead every year.
British Virgin Islands ranks 78th and Grenada ranks 78th of 215 countries.
Head to head by decade
| Decade | British Virgin Islands | Grenada | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, British Virgin Islands or Grenada?
- British Virgin Islands, at 0.2% against 0.2% in Grenada as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between British Virgin Islands and Grenada?
- 0.0%, with British Virgin Islands ahead.
- How many years of comparable data are there for British Virgin Islands and Grenada?
- 10 years are reported by both, from 2015 to 2024.
- How do British Virgin Islands and Grenada rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- British Virgin Islands ranks 78th and Grenada ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.